{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:08:08Z","timestamp":1779293288796,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005189","name":"Estonian Research and Development Council","doi-asserted-by":"publisher","award":["PRG722"],"award-info":[{"award-number":["PRG722"]}],"id":[{"id":"10.13039\/501100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["801520 HP-JA-2017"],"award-info":[{"award-number":["801520 HP-JA-2017"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115231","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:10:34Z","timestamp":1737051034000},"page":"115231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study"],"prefix":"10.1016","volume":"220","author":[{"given":"Claudia","family":"Vener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9872-8670","authenticated-orcid":false,"given":"Roberto","family":"Lillini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bonfarnuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne A.","family":"Poirel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-9833","authenticated-orcid":false,"given":"Annalisa","family":"Trama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1496-1817","authenticated-orcid":false,"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-9992","authenticated-orcid":false,"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-3657","authenticated-orcid":false,"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Maynadi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Demuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom B\u00f8rge","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Solans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1458-3254","authenticated-orcid":false,"given":"Keiu","family":"Paapsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-6364","authenticated-orcid":false,"given":"Marcela","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3537-6799","authenticated-orcid":false,"given":"Seyed Mohsen","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9243-3896","authenticated-orcid":false,"given":"Marcel","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2053-7078","authenticated-orcid":false,"given":"Damien","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-3438","authenticated-orcid":false,"given":"Rosalia","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1161-297X","authenticated-orcid":false,"given":"Adrien","family":"Guilloteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-0788","authenticated-orcid":false,"given":"Charlene M.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-2904","authenticated-orcid":false,"given":"Silvia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Sant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115231_bib1","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2025.115231_bib2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115231_bib3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115231_bib4","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","article-title":"Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: results of EUROCARE-5 population-based study","volume":"51","author":"De Angelis","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115231_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.892684","article-title":"Clear improvement in real-world chronic myeloid leukemia survival: a comparison with randomized controlled trials","volume":"12","author":"Vener","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115231_bib6","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.3390\/cancers15174388","article-title":"Epidemiological trends of haematological malignancies in Belgium 2004-2018: older patients show the greatest improvement in survival","volume":"15","author":"Henau","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2025.115231_bib7","unstructured":"Marmot M. Fair Society, Healthy Lives. The Marmot Review. Strategic review of health inequalities in England post-2010. \u3008http:\/\/www.instituteofhealthequity.org\u3009 [last accessed May 30, 2024]."},{"key":"10.1016\/j.ejca.2025.115231_bib8","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ejca.2015.07.025","article-title":"Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study","volume":"51","author":"Baili","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115231_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1470-2045(24)00141-4","article-title":"Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study","volume":"25","author":"Sant","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115231_bib10","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.ejca.2015.08.001","article-title":"The EUROCARE-5 study on cancer survival in Europe 1999\u20132007: database, quality checks and statistical analysis methods","volume":"51","author":"Rossi","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115231_bib11","series-title":"International classification of diseases for oncology (ICD-O)","author":"Fritz","year":"2000"},{"key":"10.1016\/j.ejca.2025.115231_bib12","volume":"2","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.ejca.2025.115231_bib13","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2025.115231_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data.","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.115231_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejca.2003.10.013","article-title":"Period analysis for \u2018up-to-date\u2019 cancer survival data: theory, empirical evaluation, computational realisation and applications","volume":"40","author":"Brenner","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115231_bib16","first-page":"101","article-title":"The relative survival: a statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejca.2025.115231_bib17","series-title":"The natural duration of cancer (Report on Public Health and Medical Subjects No. 33)","author":"Greenwood","year":"1926"},{"key":"10.1016\/j.ejca.2025.115231_bib18","article-title":"What is relative survival and what is its role in haematology?","volume":"36","author":"Pohar Perme","year":"2023","journal-title":"Best Pr Res Clin Haematol"},{"key":"10.1016\/j.ejca.2025.115231_bib19","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2009.25.9697","article-title":"Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers","volume":"28","author":"Janssen-Heijnen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115231_bib20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","article-title":"Standard cancer patient population for age standardising survival ratios","volume":"40","author":"Corazziari","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115231_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2025.115231_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1536867X1501500112","article-title":"Estimating and modeling relative survival","volume":"15","author":"Dickman","year":"2015","journal-title":"Stata J"},{"key":"10.1016\/j.ejca.2025.115231_bib23","first-page":"26","article-title":"Generalized linear models","volume":"2","author":"Coxe","year":"2013"},{"key":"10.1016\/j.ejca.2025.115231_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","article-title":"Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study","volume":"17","author":"Vogler","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115231_bib25","first-page":"2129","volume":"399","author":"GBD","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115231_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1470-2045(24)00187-6","article-title":"Finding the health-care expenditure that drives variation in cancer survival","volume":"25","author":"Rutherford","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:45:25Z","timestamp":1760640325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"alternative-id":["S0959804925000127"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115231","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115231"}}